A Phase 3, Randomized, Open-Label Study Evaluating DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (ASCENT-2)
A Phase 3, Randomized, Open-Label Study Evaluating DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (ASCENT-2)
The primary objective of this study is:
The secondary objectives of this study are:
Inclusion Criteria:
Exclusion Criteria:
Washington D.C., District of Columbia 20007, United States
14529 Cortez Blvd., Florida 34613, United States
Sante Fe, New Mexico 87505, United States
Kirchheim/Teck, 73230, Germany
Debrecen, H4032, Hungary
Szeged, Hungary
Belgrade, 18000, Serbia and Montenegro